Drug

Pharmacologic Class

Indication

More Information

Dermatological Disorders
Dupixent (dupilumab) Interleukin-4 receptor alpha antagonist Treatment of adult patients with prurigo nodularis. Dupixent Drug Monograph
Spevigo (spesolimab-sbzo) Humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 signaling Treatment of generalized pustular psoriasis. Spevigo Approved to Treat Generalized Pustular Psoriasis Flares
Sotyktu (deucravacitinib) Tyrosine kinase 2 inhibitor Treatment of adults with moderate to severe plaque psoriasis who are candidates for a systemic therapy or phototherapy. Sotyktu Drug Monograph
Diagnostic Agents
Elucirem and Vueway (gadopiclenol) Macrocyclic gadolinium-based contrast agents For use with magnetic resonance imaging in patients 2 years of age and older to detect and visualize lesions with abnormal vascularity in the central nervous system and the body. Gadopiclenol, a New Macrocyclic Gadolinium-Based Contrast Agent, Gets FDA Approval
Gastrohepatic Disorders
Aponvie (aprepitant) A substance P/neurokinin-1 receptor antagonist For the prevention of postoperative nausea and vomiting in adults. FDA Approves Aponvie for the Prevention of Postoperative Nausea, Vomiting
Neurologic Disorders
Relyvrio (sodium phenylbutyrate and taurursodiol) Targets the endoplasmic reticulum and mitochondrial-dependent neuronal degeneration pathways in ALS Treatment of amyotrophic lateral sclerosis in adults. Relyvrio, a New Treatment Option for ALS, Gets FDA Approval
Skysona (elivaldogene autotemcel) Gene therapy designed to add functional copies of the ABCD1 cDNA into a patient’s own hematopoietic stem cells To slow the progression of neurologic dysfunction in boys 4 to 17 years of age with early, active cerebral adrenoleukodystrophy. Skysona Gets Accelerated Approval for Early, Active Cerebral Adrenoleukodystrophy
Oncology
Imfinzi (durvalumab) Programmed death-ligand 1 blocking antibody Treatment of adults with locally advanced or metastatic biliary tract cancer, in combination with gemcitabine and cisplatin. Imfinzi Drug Monograph
Lytgobi (futibatinib) A selective and irreversible small molecule kinase inhibitor of FGFR 1, 2, 3, and 4 Treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene fusions or other rearrangements. Lytgobi Gets Accelerated Approval for Intrahepatic Cholangiocarcinoma
Pedmark (sodium thiosulfate injection) Increases antioxidant glutathione levels and inhibits intracellular oxidative stress To reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, nonmetastatic solid tumors. Pedmark Approved for Pediatric Cisplatin-Associated Ototoxicity
Retevmo (selpercatinib) Kinase inhibitor Treatment of adults with locally advanced or metastatic solid tumors with a rearranged during transfection gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. Retevmo Drug Monograph
Ophthalmic Disorders
Omlonti (omidenepag isopropyl) Selective prostaglandin E2 (EP2) receptor agonist To reduce elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Omlonti Approved for Open-Angle Glaucoma, Ocular Hypertension
Iheezo (chloroprocaine hydrochloride) An ester anesthetic Ocular surface anesthesia. Iheezo Ophthalmic Gel Approved for Ocular Surface Anesthesia
Urological Disorders
Terlivaz (terlipressin) Vasopressin analogue selective for V1 receptors To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. FDA Approves Terlivaz to Improve Kidney Function in Hepatorenal Syndrome